Lonza and Ypsomed enter into a Collaboration for Development and Manufacturing of Patch Injector-based Combination Products for Pharmaceutical customers
- The collaboration will streamline the development of patch-injector-based combination products, especially for biologics
- The resulting products aim to offer improved patient convenience by decreasing the necessary hospital visits for therapy administration
- Lonza to provide drug product formulation and process development, filling, final assembly and testing of the final drug/device combination product
- Ypsomed to leverage its patch injector platform technology and to complement it with the drug services provided by Lonza
Quote from Prof. Dr. Hanns-Christian Mahler, Head of Drug Product Services, Lonza:
"The know-how and unmatched expertise of Lonza Drug Product Services in the development, manufacturing, and testing of sterile products for subcutaneous administration is the perfect base to enable our pharmaceutical and biotech customers in the development and commercialization of YpsoDose® patch injector-based sterile products for the benefit of patients."
Quote from Ulrike Bauer, Senior Vice President Delivery Systems, Ypsomed:
"Together with strong partners such as Lonza and Schott, we offer a comprehensive solution for patch injectors so that our customers can commercialize their pharmaceuticals in YpsoDose® with a reduced time-to-market and at reduced risks. Although our platform provides extensive freedom in the choice of components and partners, the advantage of this collaboration is that the three companies bundle their expertise and provide an integrated offering."
Basel, Switzerland, 09 November 2020 – Ypsomed, a leading Swiss specialist for the development and manufacture of injection and infusion systems for self-medication, and Lonza, a leading contract development and manufacturing service provider for the pharmaceutical industry, announced today that the companies have entered into a development and manufacturing collaboration to offer comprehensive patch injector-based solutions to the pharmaceutical and biotech industry. The resulting solution aims to allow self-administration of innovative therapies to improve patient benefit and convenience.
Many patients need to receive significant numbers of injections or infusions regularly. In the future, instead of visiting a doctor or a hospital for these treatments, patients may be able to use a wearable patch injector for self-administration into subcutaneous tissue at their own homes.
Pharmaceutical and biotechnology companies interested in this technology can benefit from a reliable injection device technology platform delivered by partners with experience and capabilities in their respective fields of pharmaceutical product development and commercialization. The collaboration will provide flexibility and know-how to allow for faster and more robust development timelines to provide pharmaceutical and biotech customers with large-volume delivery options of up to 10 mL currently, for their innovative therapies.
Based on Ypsomed's prefilled, easy-to-use patch injector YpsoDose®, the companies will offer a comprehensive solution to pharmaceutical and biotech customers for easy development and commercialization of patch-injector-based therapies. Employing the 10 ml cartriQ® glass cartridge manufactured by Schott, a leading supplier of parenteral packaging to the pharmaceutical industry, Lonza's Drug Product Services (DPS) will develop drug product formulations and the filling process for customers. Lonza will fill and test cartridges and assemble, test and release the patch-injector from the components delivered by Ypsomed for patient use.
Thanks to this collaboration, customers seeking rapid access to the device for clinical trials to the commercial supply of filled, assembled, and released products using the injection devices will be able to receive an integrated contract development and manufacturing service.